Avalon Ventures’ Afraxis Licenses Entire Drug Portfolio to Genentech
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 8 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1895 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Roche’s Genentech has licensed global rights to develop and commercialise Afraxis’ entire portfolio of CNS compounds in a deal worth up to US$187...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS